GLP-1 prescribing increased faster among adults with serious mental illness than among those without serious mental illness from 2018 to 2024, according to a Sept. 2 study published in JAMA Psychiatry.
Here are five things to know:
- Among adults with an underlying condition indicating GLP-1 use, prescription rates among those with serious mental illness increased from 2.3% in 2018 to 13.7% in 2024. Rates among adults without serious mental illness increased from 1.8% to 11.1%.
- Researchers analyzed data from 104,315,456 adults, including 14,187,676 with serious mental illness. Among adults with serious mental illness, 14% had schizophrenia, 20.8% had bipolar disorder and 65.2% had major depressive disorder.
- Conditions indicating GLP-1 use were more prevalent among adults with serious mental illness, including diabetes (22.4% vs. 11.5%), obesity (42.9% vs. 21.8%), sleep apnea (17% vs. 6.3%) and overweight plus another chronic condition (16.9% vs. 8.7%).
- Among adults with diabetes, those with schizophrenia had lower GLP-1 prescription rates than those without serious mental illness. Rates among adults with schizophrenia increased from 3.4% in 2018 to 19.4% in 2024, compared with 4.5% to 23.1% among adults without serious mental illness.
- Researchers said the findings suggest clinicians view GLP-1s as safe and effective for patients with serious mental illness, with a possible exception for those with schizophrenia. They called for further research on continuity of GLP-1 use among people with serious mental illness.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
